NCT02162264已完成不适用
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8,662
- 主要终点
- Change From Baseline in the Mini-Mental State Examination (MMSE) Score
研究概览
简要总结
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
E2020
干预措施: Donepezil Hydrochloride (Drug)
结局指标
主要结局
Change From Baseline in the Mini-Mental State Examination (MMSE) Score
时间窗: Baseline, Month 3, Month 6, and Month 12
次要结局
- Investigations on adverse events and adverse drug reactions(Baseline and Month 12)
研究者
相似试验
已完成
不适用
Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-Alzheimer's DiseaseNCT01129596Eisai Co., Ltd.10,238
已完成
不适用
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseAlzheimer's DiseaseNCT01251718Eisai Co., Ltd.894
已完成
不适用
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).Dementia With Lewy Body DiseaseNCT02448784Eisai Co., Ltd.591
未知
Unknown
Post-marketing surveillance of donepezil hydrochloride -Investigation of the clinical safety and effectiveness in patients with Alzheimer's DiseaseAlzheimer's DiseaseJPRN-jRCT1080221997Eisai Co., Ltd.1,000
未知
Unknown
Post-marketing surveillance of donepezil hydrochloride Dementia with Lewy bodies/long-term administratioDementia with Lewy bodiesJPRN-jRCT1080222854Eisai Co., Ltd.500